Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.
Bria E, Massari F, Maines F, Pilotto S, Bonomi M, Porta C, Bracarda S, Heng D, Santini D, Sperduti I, Giannarelli D, Cognetti F, Tortora G, Milella M. Bria E, et al. Among authors: heng d. Crit Rev Oncol Hematol. 2015 Jan;93(1):50-9. doi: 10.1016/j.critrevonc.2014.08.001. Epub 2014 Aug 18. Crit Rev Oncol Hematol. 2015. PMID: 25195095 Review.
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, MacKenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY; International mRCC Database Consortium. Al-Marrawi MY, et al. Target Oncol. 2013 Sep;8(3):203-209. doi: 10.1007/s11523-012-0252-7. Epub 2013 Jan 9. Target Oncol. 2013. PMID: 23300029 Free PMC article.
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Kroeger N, et al. Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054. Epub 2014 Dec 15. Eur Urol. 2015. PMID: 25524810
The prospect of precision therapy for renal cell carcinoma.
Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. Ciccarese C, et al. Among authors: heng d. Cancer Treat Rev. 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003. Epub 2016 Jul 12. Cancer Treat Rev. 2016. PMID: 27453294 Review.
489 results